$870,000 20%
Total revenue, Q2 '26 ().

Did TherapeuticsMD Beat Earnings?

TherapeuticsMD (TXMD) reported Q2 '26 revenue of $870,000, down 8.7% year-over-year, with reported EPS of $0.01.

AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — TherapeuticsMD’s job postings, web traffic, and employee business outlook. See the full TXMD stock analysis or the earnings calendar for upcoming reports.

TherapeuticsMD Quarterly Financial Trends ()

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Revenue550,000670,000390,000950,000780,000890,000720,000870,000
Gross margin100.0%100.0%100.0%100.0%100.0%100.0%55.1%100.0%
Operating margin-157.0%-47.8%-303.6%-73.0%-105.9%-167.5%-99.9%-93.9%
Net income-610,000250,000-650,000550,000150,000-620,00095,000160,000
Net margin-111.3%37.8%-166.2%57.9%19.4%-69.3%13.1%17.8%
EPS$0.02$0.02$0.05$0.01

TherapeuticsMD Earnings Trend Analysis

Over the eight quarters from Q3 '24 to Q2 '26, TherapeuticsMD’s quarterly revenue moved from $550,000 to $870,000. Net margin expanded from -111.3% to 17.8%, against a 100% gross margin in the most recent quarter — a read on whether revenue growth is translating into profit. TherapeuticsMD has beaten Wall Street EPS estimates in 0 of its last 1 reported quarters.

When Is TherapeuticsMD’s Next Earnings Date?

TherapeuticsMD reports earnings on a quarterly schedule. Its most recent report covered Q2 '26. For the confirmed upcoming date — and every other company reporting soon — see the TXMD earnings calendar.

Frequently Asked Questions: TherapeuticsMD Earnings

TherapeuticsMD's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.

TherapeuticsMD reported Q2 '26 EPS of $0.01 on revenue of $870,000 (-8.7% YoY). TherapeuticsMD reported EPS of $0.01.

TherapeuticsMD reported Q2 '26 revenue of $870,000, down 8.7% from the same quarter a year earlier.

Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the TXMD AI Score.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.